Strengthening the Healthcare Business Through the Acquisition of an Animal-Derived Blood Products Business
First written in FY2022. 1 of 3 entries say "Achieved", first in FY2023-Q1. Latest entry: FY2023.
No other company in this theme has enough history to compare yet.
- FY2023RestatedAnnual report
「Completed on 19 May 2022.」
The annual report also confirms the completion of the acquisition of Moregate’s animal-derived blood products manufacturing and sales business through ANZCO FOODS Ltd. and its positioning as a measure to strengthen the healthcare business. - FY2023-Q1AchievedAnnual report
「At a meeting of the Board of Directors held on 18 March 2022, the company resolved to enter into a business transfer agreement, through its consolidated subsidiary ANZCO FOODS Ltd., to acquire the animal-derived blood products manufacturing and sales business held by Moregate Exports Pty. Ltd. and Moregate Exports Ltd., and completed the transaction on 19 May 2022.」
The acquisition of Moregate’s animal-derived blood products manufacturing and sales business through ANZCO FOODS Ltd. was completed on 19 May 2022, moving from the agreement stage to the completion stage of the business acquisition. - FY2022First statedAnnual report
「Animal-derived blood products are expected to achieve high growth going forward for vaccines, regenerative medicine and clinical diagnostics, supported by strong demand from pharmaceutical and biotechnology companies. The company therefore resolved to enter into the business transfer agreement, having determined that the transaction would expand the scale of the group’s healthcare business and increase its added value.」
As part of the initiatives for new businesses and markets under Medium-Term Management Plan 2023, the company entered into an agreement in March 2022, through ANZCO FOODS Ltd., to acquire Moregate’s animal-derived blood products manufacturing and sales business. The business combination date is 19 May 2022.